HalfLytely and Bisacodyl

HalfLytely and Bisacodyl is a brand name of bisacodyl/polyethylene glycol 3350/potassium chloride/sodium bicarbonate/sodium chloride, approved by the FDA in the following formulation(s):

HALFLYTELY (bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride - tablet, delayed release, for solution; oral)

• 
  Manufacturer: BRAINTREE
  
  Approval date: July 16, 2010
  
  Strength(s): 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM ^[RLD]

Has a generic version of HalfLytely and Bisacodyl been approved?

No. There is currently no therapeutically equivalent version of HalfLytely and Bisacodyl available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of HalfLytely and Bisacodyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of bowel cleansing
  Patent 7,291,324
  Issued: November 6, 2007
  Inventor(s): Dennett, Jr.; Edmund V. & Raleigh, Jr.; Robert M. & Cleveland; Mark V B. & Pelham; Russell W.
  Assignee(s): Braintree Laboratories Inc.
  Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.
  
  Patent expiration dates:
  
  
  • October 22, 2022
    
    ✓ 
    Patent use: GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 24, 2010 - NEW PRODUCT
  
  
  • July 16, 2013 - NEW PRODUCT
  
  

See also...

• HalfLytely Consumer Information (Drugs.com)
• Bisacodyl Tablets Bowel Prep Kit Consumer Information (Wolters Kluwer)
• HalfLytely Solution Consumer Information (Wolters Kluwer)
• Half Lytely and Bisacodyl Lemon Lime Consumer Information (Cerner Multum)
• HalfLytely and Bisacodyl Consumer Information (Cerner Multum)
• HalfLytely and Bisacodyl with Flavor Packs Consumer Information (Cerner Multum)
• Bisacodyl Tablet Bowel Prep Kit Solution Consumer Information (Wolters Kluwer)
• Polyethylene Glycol/Electrolytes Solution Consumer Information (Wolters Kluwer)
• Bisacodyl and polyethylene glycol (PEG) 3350 with electrolytes Consumer Information (Cerner Multum)